Pollak P, Gaio J M, Hommel M, Pellat J, Perret J
Psychopharmacology (Berl). 1985;85(2):236-9. doi: 10.1007/BF00428422.
Tiapride, a selective D2 dopaminergic receptor blocking agent from the substituted benzamide class, was evaluated in a blind video-controlled trial in 10 psychiatric patients with tardive dyskinesia. There was a significant decrease in dyskinesia with a parallel increase in parkinsonism. This relationship between two opposite effects on movement suggests a common pathophysiological basis lying on a reciprocal hyper- and hypoactivity of the dopaminergic striatal system. Nevertheless, other mechanisms may be involved, for the evolution of individual parkinsonian and dyskinesia scores is not necessarily opposite: the tiapride-induced parkinsonism was generally acceptable and in two cases, the dyskinesia scores were reduced without an increase in parkinsonism. Therefore, more dyskinetic patients have to be evaluated in long-term studies with tiapride, before this drug could be recommended in tardive dyskinesia, when dyskinetic movements become intolerable.
硫必利是一种来自取代苯甲酰胺类的选择性D2多巴胺能受体阻断剂，在一项针对10名迟发性运动障碍精神病患者的盲法视频对照试验中进行了评估。运动障碍显著减少，同时帕金森症症状相应增加。这两种对运动的相反作用之间的关系表明，其共同的病理生理基础在于多巴胺能纹状体系统的相互亢进和减退。然而，可能还涉及其他机制，因为个体帕金森症和运动障碍评分的变化不一定相反：硫必利引起的帕金森症通常是可以接受的，在两例患者中，运动障碍评分降低而帕金森症症状并未加重。因此，在硫必利可被推荐用于迟发性运动障碍（当运动障碍变得无法忍受时）之前，必须在更多的运动障碍患者中进行硫必利的长期研究评估。
